Literature DB >> 2568216

Neural mechanisms in disorders of movement.

A R Crossman1.   

Abstract

1. Experimental models of ballism, chorea and Parkinson's disease have been developed in the primate, and the underlying neural mechanisms which mediate these disorders of movement have been investigated using the 2-deoxyglucose uptake technique. 2. In ballism, the subthalamic nucleus is either lesioned or underactive. Because of the excitatory nature of subthalamic efferent fibres, this leads to abnormal underactivity of neurons in the medical segment of the globus pallidus which project to the ventral anterior and ventral lateral nuclei of the thalamus, and to the pedunculopontine nucleus of the caudal midbrain. 3. In chorea, there is underactivity of GABAergic striatal (putaminal) neurons which project to the lateral segment of the globus pallidus. This leads to overacting of lateral pallidal neurons and, thus, physiological inhibition of the subthalamic nucleus. Common neural mechanisms, therefore, underlie the appearance of dyskinesia in ballism and chorea. 4. In parkinsonism, there is overactivity of putaminal neurons projecting to the lateral pallidal segment. This results in excessive inhibition of lateral pallidal neurons and, as a consequence, disinhibition of the subthalamic nucleus. Overactivity of the subthalamic nucleus provides excessive drive upon medial pallidal neurons projecting to thalamic and pedunculopontine nuclei.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568216     DOI: 10.1016/0300-9629(89)90201-6

Source DB:  PubMed          Journal:  Comp Biochem Physiol A Comp Physiol        ISSN: 0300-9629


  26 in total

1.  Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus.

Authors:  T Shindou; A Mori; H Kase; M Ichimura
Journal:  J Physiol       Date:  2001-04-15       Impact factor: 5.182

2.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.

Authors:  J E Nash; J M Brotchie
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

4.  Changing views of basal ganglia circuits and circuit disorders.

Authors:  Mahlon DeLong; Thomas Wichmann
Journal:  Clin EEG Neurosci       Date:  2010-04       Impact factor: 1.843

Review 5.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 6.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

7.  Autonomous initiation and propagation of action potentials in neurons of the subthalamic nucleus.

Authors:  Jeremy F Atherton; David L Wokosin; Sankari Ramanathan; Mark D Bevan
Journal:  J Physiol       Date:  2008-10-02       Impact factor: 5.182

8.  Selective innervation of neostriatal interneurons by a subclass of neuron in the globus pallidus of the rat.

Authors:  M D Bevan; P A Booth; S A Eaton; J P Bolam
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

Review 9.  Update on models of basal ganglia function and dysfunction.

Authors:  Mahlon DeLong; Thomas Wichmann
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

10.  Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.

Authors:  Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.